A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
about
Is a multivalent hand, foot, and mouth disease vaccine feasible?Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic MouseEV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseasesStructural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal AntibodyEfficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in MiceDifferent microRNA profiles reveal the diverse outcomes induced by EV71 and CA16 infection in human umbilical vein endothelial cells using high-throughput sequencing.Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn miceEV71 vaccine, an invaluable gift for children.Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.Development and evaluation of a rapid recombinase polymerase amplification assay for detection of coxsackievirus A6.Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluationVirus-Like Particles Produced in Pichia Pastoris Induce Protective Immune Responses Against Coxsackievirus A16 in Mice.Review of enterovirus 71 vaccines.Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide.Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral CapsidsEnterovirus 71: a whole virion inactivated enterovirus 71 vaccine.Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.Suppression of the toll-like receptor 7-dependent type I interferon production pathway by autophagy resulting from enterovirus 71 and coxsackievirus A16 infections facilitates their replication.microRNA-4516 Contributes to Different Functions of Epithelial Permeability Barrier by Targeting Poliovirus Receptor Related Protein 1 in Enterovirus 71 and Coxsackievirus A16 Infections.Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth diseaseEpidemic dynamics, interactions and predictability of enteroviruses associated with hand, foot and mouth disease in Japan
P2860
Q27010349-F4997436-7FE4-4F80-A9F5-E61051A04CC2Q27321616-EE22F206-D2D1-407E-B05B-72BA84301524Q28076658-1B1C06FE-23E0-4076-8868-055F4C80A6D3Q28550496-66D53401-6472-4428-BC5A-AB106BE6CDA9Q28606867-4D2030BD-2E6B-4458-818F-BF14319A04F9Q33713090-6C861F6E-07AD-41FE-963C-D64B79736F0DQ33723474-CF01BF45-7686-45C7-AD42-0ACEF72CB96EQ34540559-8982EB2F-90DC-4515-87E8-465B130BBB26Q34981056-2ED0CB4A-9FC6-427A-8135-4520974CB324Q35917729-AECBDB6D-92F3-46CE-A3B8-6B30811D1972Q36159082-5B8FA472-C99D-4E4E-9C3A-E3ACAE27354DQ37281676-8CDC956C-A424-4680-82FB-67164EC65C40Q37282912-47A290FD-A8C2-46B2-8480-853CDBA32D02Q38263484-880B34EE-062C-4079-9067-CED884EFFAABQ38538070-142F1EAD-04F2-4B6B-868D-1F74703F38AEQ38763206-0FE5EA13-C45A-488F-A060-47C6159E984FQ38840182-79F31A25-66CF-49E0-8055-2A3E73007BC0Q47600312-A2D50B2B-954D-4B89-862E-1280B79B1365Q47606446-9B2F48A2-10C0-46C8-9130-CE2721BE68ADQ52691734-6693324A-E642-4C1A-81BA-40B40B230AB4Q55967992-60F9E6EE-77A5-44DA-8FDF-3C4610702D11Q58744923-7976100B-6C49-4F82-B18F-9DCD2BED5C90
P2860
A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A combination vaccine comprisi ...... immunity against both viruses.
@en
A combination vaccine comprisi ...... immunity against both viruses.
@nl
type
label
A combination vaccine comprisi ...... immunity against both viruses.
@en
A combination vaccine comprisi ...... immunity against both viruses.
@nl
prefLabel
A combination vaccine comprisi ...... immunity against both viruses.
@en
A combination vaccine comprisi ...... immunity against both viruses.
@nl
P2093
P1433
P1476
A combination vaccine comprisi ...... immunity against both viruses.
@en
P2093
Qibin Leng
Qingwei Liu
Zhiqiang Ku
P304
P356
10.1016/J.VACCINE.2014.03.012
P407
P50
P577
2014-03-18T00:00:00Z